Healy Mark A, Yin Huiying, Reddy Rishindra M, Wong Sandra L
Affiliations of authors:Department of Surgery (MAH, RMR, SLW) and Center for Healthcare Outcomes and Policy (MAH, HY, SLW), University of Michigan , Ann Arbor, MI.
J Natl Cancer Inst. 2016 Feb 22;108(7). doi: 10.1093/jnci/djv429. Print 2016 Jul.
Positron emission tomography (PET) scans are often used in cancer patients for staging, restaging, and monitoring for treatment response. These scans are also often used to detect recurrence in asymptomatic patients, despite a lack of evidence demonstrating improved survival. We sought to evaluate utilization of PET for this purpose and relationships with survival for patients with lung and esophageal cancers.
Using national Surveillance, Epidemiology, and End Results (SEER) and Medicare-linked data, we identified incident patient cases from 2005 to 2009, with follow-up through 2011. We identified cohorts with primary lung (n = 97 152) and esophageal (n = 4446) cancers. Patient and tumor characteristics were used to calculate risk-adjusted two-year overall survival. Using Medicare claims, we examined PET utilization in person-years (to account for variable time in cohorts), excluding scans for staging and for follow-up of CT findings. We then stratified hospitals by quintiles of PET utilization for adjusted two-year survival analysis. All statistical tests were two-sided.
There was statistically significant variation in utilization of PET. Lowest vs highest utilizing hospitals performed .05 (SD = 0.04) vs 0.70 (SD = 0.44) scans per person-year for lung cancer and 0.12 (SD = 0.06) vs 0.97 (SD = 0.29) scans per person-year for esophageal cancer. Despite this, for those undergoing PET, lowest vs highest utilizing hospitals had an adjusted two-year survival of 29.0% (SD = 12.1%) vs 28.8% (SD = 7.2%) for lung cancer (P = .66) and 28.4% (SD = 7.2%) vs 30.3% (SD = 5.9%) for esophageal cancer (P = .55).
Despite statistically significant variation in use of PET to detect tumor recurrence, there was no association with improved two-year survival. These findings suggest possible overuse of PET for recurrence detection, which current Medicare policy would not appear to substantially affect.
正电子发射断层扫描(PET)常用于癌症患者的分期、重新分期以及治疗反应监测。尽管缺乏证据表明其能提高生存率,但这些扫描也常被用于检测无症状患者的复发情况。我们试图评估PET在此方面的应用情况以及与肺癌和食管癌患者生存率的关系。
利用国家监测、流行病学和最终结果(SEER)以及与医疗保险相关的数据,我们确定了2005年至2009年的新发患者病例,并随访至2011年。我们确定了原发性肺癌(n = 97152)和食管癌(n = 4446)的队列。患者和肿瘤特征用于计算风险调整后的两年总生存率。利用医疗保险理赔数据,我们以人年为单位检查PET的使用情况(以考虑队列中的可变时间),排除用于分期和CT检查结果随访的扫描。然后,我们根据PET使用的五分位数对医院进行分层,以进行调整后的两年生存分析。所有统计检验均为双侧检验。
PET的使用存在统计学上的显著差异。肺癌患者中,PET使用最少的医院与人年扫描次数为0.05(标准差 = 0.04),而使用最多的医院为0.70(标准差 = 0.44);食管癌患者中,使用最少的医院与人年扫描次数为0.12(标准差 = 0.06),而使用最多的医院为0.97(标准差 = 0.29)。尽管如此,对于接受PET检查的患者,PET使用最少的医院与最多的医院相比,肺癌患者调整后的两年生存率分别为29.0%(标准差 = 12.1%)和28.8%(标准差 = 7.2%)(P = 0.66),食管癌患者分别为28.4%(标准差 = 7.2%)和30.3%(标准差 = 5.9%)(P = 0.55)。
尽管在使用PET检测肿瘤复发方面存在统计学上的显著差异,但与两年生存率的提高并无关联。这些发现表明PET在复发检测方面可能存在过度使用的情况,而目前的医疗保险政策似乎对此影响不大。